Market Intelligence, Clinical Progress, and High-Purity Reagents for Endocrine-Resistant Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCNE2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCNE2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CCNE2 Products |
| Gene Delivery | CCNE2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CCNE2 Products |
| Benchmark Ab | Anti-CCNE2 Recombinant Antibody Recombinant positive control for assay validation. |
View CCNE2 Products |
| Validator | CCNE2 siRNA Set For knockdown verification. |
View CCNE2 Products |
| Related Target A | CDK2 Primary catalytic partner forming the active oncogenic G1/S kinase complex. |
View CDK2 Products |
| Related Target B | CCNE1 Highly homologous cyclin; critical for selectivity and cross-reactivity profiling. |
View CCNE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against CCNE1 homolog | Highly purified CCNE2 and CCNE1 panel proteins strictly verified by mass spectrometry. |
| Reconstitution of active CCNE2/CDK2 complex | Co-expressed or highly compatible monomeric proteins with verified sequence integrity and theoretical MW. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CCNE2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCNE2 therapeutics is intensifying, with major players shifting focus from traditional non-selective CDK inhibitors to highly selective CDK2/CCNE2 complex inhibitors. As first-generation CDK4/6 inhibitors encounter resistance in HR+/HER2- breast cancer, the next wave of R&D is targeting the CCNE2/CDK2 pathway to overcome acquired endocrine therapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (CDK2/CCNE) | Pfizer, Blueprint Medicines, Incyte | HR+/HER2- Breast Cancer, Ovarian Cancer | Kinase Selectivity Assay (Need high-purity CCNE2 and CDK2 proteins) |
| PROTAC / Degraders | Carrick Therapeutics, Arvinas | Endocrine-Resistant Solid Tumors | Ternary Complex Formation (Need high-purity recombinant CCNE2/CDK2) |
| Gene Therapy / RNAi | Academic Institutes, Biotech Startups | Advanced Refractory Malignancies | Knockdown Validation (Need Sequence-Verified siRNA and Lentivirus) |